Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapy.

European journal of cancer (Oxford, England : 1990)·2025
Same author

Retreatment, rechallenge, and escalation with subsequent immune checkpoint inhibitor therapies across cancers after initial failure.

ESMO open·2025
Same author

Neoadjuvant intralesional targeted immunocytokines (daromun) in stage III melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

Early switch from run-in with targeted to immunotherapy in advanced BRAF<sup>V600</sup>-positive melanoma: final results of the randomised phase II ImmunoCobiVem trial.

ESMO open·2025
Same author

Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial.

European journal of cancer (Oxford, England : 1990)·2023
Same author

Single-agent anti-PD-1 or combined with ipilimumab in patients with mucosal melanoma: an international, retrospective, cohort study.

Annals of oncology : official journal of the European Society for Medical Oncology·2022

Related Experiment Video

Updated: Feb 13, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
07:05

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: February 23, 2024

3.8K

[All you need to know about methylphenidate (and dared not ask)].

L Zimmer1, P Fourneret2

  • 1Hospices civils de Lyon, groupement hospitalier Est, Lyon, 69677 Bron cedex, France; Université Claude-Bernard-Lyon 1, université de Lyon, Lyon, France; Centre de recherche en neurosciences de Lyon, CNRS UMR 5292, Inserm U1028, 69677 Bron, France; CERMEP-imagerie du vivant, 69677 Bron, France.

Archives De Pediatrie : Organe Officiel De La Societe Francaise De Pediatrie
|March 17, 2018
PubMed
Summary

Methylphenidate (MPH) is an effective ADHD treatment, but fears limit its use in France. This article clarifies scientific data to support its appropriate prescription for children and adolescents.

Keywords:
Attention deficit disorderComorbiditiesExecutive functionsMethylphenidateNeurodevelopmental disordersPathophysiology

More Related Videos

Design of a Cyclic Pressure Bioreactor for the Ex Vivo Study of Aortic Heart Valves
07:12

Design of a Cyclic Pressure Bioreactor for the Ex Vivo Study of Aortic Heart Valves

Published on: August 23, 2011

16.3K
Protocol for Developing a Femur Osteotomy Model in Wistar Albino Rats
05:43

Protocol for Developing a Femur Osteotomy Model in Wistar Albino Rats

Published on: August 31, 2022

3.4K

Related Experiment Videos

Last Updated: Feb 13, 2026

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
07:05

Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF

Published on: February 23, 2024

3.8K
Design of a Cyclic Pressure Bioreactor for the Ex Vivo Study of Aortic Heart Valves
07:12

Design of a Cyclic Pressure Bioreactor for the Ex Vivo Study of Aortic Heart Valves

Published on: August 23, 2011

16.3K
Protocol for Developing a Femur Osteotomy Model in Wistar Albino Rats
05:43

Protocol for Developing a Femur Osteotomy Model in Wistar Albino Rats

Published on: August 31, 2022

3.4K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Methylphenidate (MPH) is the sole psychostimulant available in France for attention and behavior disturbances in attention deficit disorder with or without hyperactivity (ADHD).
  • MPH prescription has expanded to other pediatric neurodevelopmental disorders involving attentional deficits or executive function weaknesses.
  • Despite extensive evidence supporting its efficacy and tolerability, MPH use is restricted due to practitioner and family concerns.

Purpose of the Study:

  • To provide a concise and nuanced overview of scientific data supporting the use of Methylphenidate (MPH).
  • To address and clarify common fears and prejudices surrounding MPH prescription in pediatric populations.
  • To frame the appropriate justification and guidelines for MPH use based on approved scientific evidence.

Main Methods:

  • Review of scientific literature and clinical data on Methylphenidate (MPH).
  • Synthesis of information from psychiatric and neuropharmacological perspectives.
  • Analysis of evidence from over 400 randomized controlled and double-blind studies.

Main Results:

  • Methylphenidate (MPH) is a well-validated and effective treatment for ADHD and related disorders.
  • Studies demonstrate good tolerance of MPH when prescribed for approved indications.
  • Despite evidence, significant barriers to MPH prescription persist due to misconceptions.

Conclusions:

  • Scientific data robustly supports the efficacy and safety of Methylphenidate (MPH) for specific pediatric neurodevelopmental disorders.
  • Addressing misconceptions and providing clear scientific information is crucial for optimizing MPH treatment.
  • This article aims to guide the justified and appropriate prescription of MPH in France.